✦ LIBER ✦

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

✍ Scribed by Mark E. Polhemus; Alan J. Magill; James F. Cummings; Kent E. Kester; Chris F. Ockenhouse; David E. Lanar; Sheetij Dutta; Arnoldo Barbosa; Lorraine Soisson; Carter L. Diggs; Sally A. Robinson; John D. Haynes; V. Ann Stewart; Lisa A. Ware; Clara Brando; Urszula Krzych; Robert A. Bowden; Joe D. Cohen; Marie-Claude Dubois; Opokua Ofori-Anyinam; Els De-Kock; W. Ripley Ballou; D. Gray Heppner Jr.

Book ID: 116959695
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 646 KB
Volume: 25
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2007.03.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 randomized double-blind safety a

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

✍ José A. Stoute; Joash Gombe; Mark R. Withers; Joram Siangla; Denise McKinney; Me 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Phase 2a trial of 0, 1, and 3 month and

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

✍ Kent E. Kester; James F. Cummings; Christian F. Ockenhouse; Robin Nielsen; B. Te 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 834 KB